Bradley J. Monk, MD, FACS, FACOG

Experts in gynecologic oncology provide insight on available patient assistance programs to help lower costs of PARP inhibitors for the treatment of ovarian cancer, and how pharmacists can aid in obtaining this information.

Sarah Hayward, PharmD, BCOP, leads the discussion on strategies used to keep the healthcare team well-informed and up to date on emerging data about PARP inhibitors for the treatment of ovarian cancer.

Bradley J. Monk, MD, FACS, FACOG, leads the discussion on upcoming combination therapy regimens with PARP inhibitors for the treatment of ovarian cancer.

Drs Bradley J. Monk, Sarah Hayward, and Jennifer MacDonald comment on monitoring and managing adverse events with PARP inhibitor therapy in patients with ovarian cancer in the frontline maintenance setting.

Bradley J. Monk, MD, FACS, FACOG, and Jennifer MacDonald, PharmD, BCOP, share insight on improving outcomes and optimizing therapy with PARP inhibitors in the frontline maintenance setting for ovarian cancer.

Dr Sarah Hayward leads the discussion on optimal approaches to influence patient compliance to PARP inhibitor therapy for frontline maintenance in ovarian cancer.

Bradley J. Monk, MD, FACS, FACOG, leads the discussion on the efficacy of currently approved PARP inhibitors used in the first-line maintenance setting for ovarian cancer and how pharmacists can help patients overcome access barriers.

Sarah Hayward, PharmD, BCOP, leads the discussion on common toxicities and when to create dose adjustments for first-line maintenance therapy in patients with ovarian cancer.

Experts in gynecologic oncology provide insight on educating patients with ovarian cancer on the duration of maintenance therapy.

Drs Jennifer MacDonald, Bradley J. Monk, and Sarah Hayward review current FDA-approved PARP inhibitors for first-line maintenance therapy for patients with ovarian cancer.

Bradley J. Monk, MD, FACS, FACOG, leads the discussion on approaching treatment selection of PARP inhibitors for the treatment of ovarian cancer.

Sarah Hayward, PharmD, BCOP, and Bradley J. Monk, MD, FACS, FACOG, compare the safety and efficacy among PARP inhibitors—niraparib, olaparib, and rucaparib—for ovarian cancer treatment.

Sarah Hayward, PharmD, BCOP; Jennifer MacDonald, PharmD, BCOP; and Bradley J. Monk, MD, FACS, FACOG, discuss the relevance of PARP inhibition in the treatment of ovarian cancer and comment on the use of biomarker testing for treatment initiation.